VMS Market Regulation Gets Targeted Funding In US FDA Budget; OTC Switches Get Question
Executive Summary
In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.
You may also be interested in...
US Hemp Product Industry ‘Dying On Vine’ Without Lawful Use Legislation Or Enforcement Guidance
FDA’s tolerance of sales of hemp-containing supplements isn’t the assurance industry needs for investing in development of ingredients and products which have been shown to provide various health benefits.
US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate
Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.
COVID-19 Claim Warnings To US CBD Firms? Yes; References To Unlawful Use Of Hemp? No
Seven of nine firms targeted in US regulators’ recent warning letters about unlawful COVID-19 claims are offering supplements containing hemp ingredients. Former naturopathic physician sentenced to prison and probation for conviction on charges linked to offering bogus COVID-19 treatments.